Skip links

Athenex – Unpopular Operating Officer

While his resume appears impressive, Athenex Chief Operating Officer Jeffrey Yordon has always been in the proximity of disaster, including two class action lawsuits.


October 29, 2019 – As we move into the sixth installment of our coverage on Athenex, Viceroy reiterate our view that Oraxol is obsolete in the modern medicine, and that Athenex will be effectively bankrupt by mid-2020 with no profitable operations given management’s overenthusiastic spending habits.

This report further exposes management’s ties to impropriety and provides a broader summary of Athenex’s management & director teams.

  • Yordon’s executive career started as President of LyphoMed, who’s CEO was sued by acquiring entity, Fujisawa Pharmaceutical.
    • Fujisawa claimed LyphoMed filed false information with the FDA in connection with thirty five ANDAs. Information was either misrepresented, destroyed or was not recorded where it concerned adverse test results.
    • LyphoMed’s CEO was none other than John Kapoor of Insys Therapeutics fame.
  • Yordon claims to have founded Gensia Pharmaceuticals, when the business was in fact acquired from Kedall Co. while Yordon was employed at Gensia’s topco.
    • Gensia’s share price collapsed upon flagship heart medication showing no statistical benefits.
  • While employed at American Pharmaceutical Partners, Yordon and other senior management were sued for making misleading statements about the prospects of an anti-cancer drug.
  • While director of Sagent, shareholders sued the company alleging that the board and its advisors failed to negotiate a fair deal for the company’s shareholders in a sale; agreeing to certain terms which only benefitted management.
    • Yordon was CEO at the time of the engagement of the company’s investment bankers and establishment of the board’s “strategic committee” to evaluate such decisions.

We have already highlighted management’s involvement in Sino Forest, GCL Silicon/Poly, Suntech, Chelsea Therapeutics, the world’s largest illegal taxol smuggling operation, and now LyphoMed, Gensia and Sagent. It is mind blowing that Athenex would continue to associate with any one  of these farces, let alone a collection such as this.

In light of all of the issues and questions Viceroy have highlighted, it is also alarming to shareholders that Athenex have not addressed a single point, opting instead to simply state we have published “inaccurate information”.

Where are the inaccuracies, Athenex?

Viceroy remain short Athenex.

A link to Viceroy’s previous reports are as follows:

Report 1:

Report 2:

Report 3:

Report 4:

Report 5:

Important Disclaimer – Please read and acknowledge before continuing

Viceroy Research LLC are an investigative financial research group registered in Delaware, USA.

Our research reports have been prepared for educational purposes only and expresses our opinions. Our reports and any statements made in connection with them are the authors’ opinions, which have been based upon publicly available facts, field research, information, and analysis through our due diligence process, and are not statements of fact. All expressions of opinion are subject to change without notice, and we do not undertake to update or supplement any reports or any of the information, analysis and opinion contained in them. We believe that the publication of our opinions about public companies that we research is in the public interest. We are entitled to our opinions and to the right to express such opinions in a public forum. You can access any information or evidence cited in this report or that we relied on to write this report from information in the public domain.

To the best of our ability and belief, all information contained herein is accurate and reliable, and has been obtained from public sources we believe to be accurate and reliable, and who are not insiders or connected persons of the stocks covered herein or who may otherwise owe any fiduciary duty or duty of confidentiality to the issuer. We have a good-faith belief in everything we write; however, all such information is presented “as is,” without warranty of any kind – whether express or implied.

In no event will we be liable for any direct or indirect trading losses caused by any information available on this report. Think critically about our opinions and do your own research and analysis before making any investment decisions. We are not registered as an investment advisor in any jurisdiction. By downloading, reading or otherwise using our research reports, you agree to do your own research and due diligence before making any investment decision with respect to securities discussed herein, and by doing so, you represent to us that you have sufficient investment sophistication to critically assess the information, analysis and opinions in this report. You should seek the advice of a security professional regarding your stock transactions.

This website, all documents contained herein or any information herein should not be interpreted as an offer, a solicitation of an offer, invitation, marketing of services or products, advertisement, inducement, or representation of any kind, nor as investment advice or a recommendation to buy or sell any investment products or to make any type of investment, or as an opinion on the merits or otherwise of any particular investment or investment strategy.

Any examples or interpretations of investments and investment strategies or trade ideas are intended for illustrative and educational purposes only and are not indicative of the historical or future performance or the chances of success of any particular investment and/or strategy.

You should assume that the authors have a direct or indirect interest/position in all stocks (and/or options, swaps, and other derivative securities related to the stock) and bonds covered herein, and therefore stand to realize monetary gains in the event that the price of either declines.

The authors may continue transacting directly and/or indirectly in the securities of issuers covered herein for an indefinite period and may be long, short, or neutral at any time hereafter regardless of their initial recommendation.